Hospital Injectable Products · LP-192
Insulin NPH Injection
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-192Hospital Injectable Products
- Generic identity
- Insulin NPHInjection
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-192
- Generic ingredient
- Insulin NPH
- Dosage form
- Injection
- Proposed strength
- 100 IU/mL vial
- Proposed pack
- 10 mL vial; cold-chain carton
- Portfolio category
- Hospital Injectable Products
About Insulin NPH
NPH insulin, also called isophane insulin, is an intermediate-acting insulin formulation. Its action profile differs from soluble regular insulin and from long-acting insulin analogues. The insulin identity and formulation should be explicitly verified rather than inferred from a family name. This catalogue entry describes a vial presentation and is not an instruction for changing an existing diabetes regimen.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Treatment planning considers the person’s glucose pattern, meals, activity, other therapies and ability to monitor and respond to low glucose. An intermediate-acting preparation has a distinct role within that plan. NPH formulations require their own preparation and inspection instructions. General human-insulin references are educational and do not establish a candidate’s onset, duration, permitted route or interchangeability with another manufacturer’s product.
Important safety considerations
Hypoglycaemia can be serious and may occur at times related to the formulation’s action profile. Incorrect resuspension, concentration selection or measurement can cause inconsistent delivery. Allergy, local skin changes and hypokalaemia can occur. Illness, missed food, exercise and renal impairment may change insulin needs. Vials, syringes and other devices must be appropriate for the prescribed concentration. Severe low-glucose symptoms require prompt action according to the patient’s clinical care plan.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The source specifies a vial labelled 100 IU/mL. Confirm insulin species or recombinant identity, suspension properties and approved administration route. Do not apply the appearance or handling rules of a clear soluble insulin to an NPH preparation.
Follow the exact insulin label for storage, transport, preparation of the suspension and the permitted period after first use. Protect identity and concentration throughout dispensing. Appearance, mixing technique and excursion decisions require product-specific instructions; no universal in-use period is assigned here.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Review insulin identity, the individualized diabetes plan, monitoring, hypoglycaemia education and compatible measuring equipment. Confirm the exact authorized vial and handling instructions.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Insulin NPH
- Dosage form / presentation
- Injection
- Catalogue strength
- 100 IU/mL vial
- Catalogue pack
- 10 mL vial; cold-chain carton
- Portfolio category
- Hospital Injectable Products
Layer 02
Unresolved product-specific fields
- P022 — The catalogue says “Insulin NPH” at 100 IU/mL in a 10 mL vial, but it does not establish the exact insulin species/source, whether “NPH” corresponds to an isophane human-insulin formulation, or the complete excipient/suspension system.
- The external insulin-isophane label demonstrates why suspension identity, concentration, container and handling are formulation-specific. It does not identify LP-192 or establish equivalence.
- Approved indication, patient eligibility and dosing or test interpretation are not established by this portfolio record.
- Registration/authorization, manufacturing or site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- DailyMed: HUMULIN N (insulin isophane human) injectable suspension — external comparatorgovernment-hosted external product label
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Controlled insulin master and finished-product specification confirming exact insulin identity/source, formulation type, concentration, excipients, vial closure, authorised route(s) and product-specific handling/storage.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-192, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-192.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.